Immutep
Germany - BerlinBiotechnology
Focus: Immutep is a Berlin-based biotechnology company specializing in cell therapies and antibodies focused on immuno-oncology. The company operates as a clinical-stage biotech with a diversified pipeline across multiple cancer indications.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Open Jobs
3
Should You Work at Immutep?
AI assessmentHigh-risk, high-reward immuno-oncology play suitable only for scientists and clinicians willing to bet on early-stage pipeline depth and Berlin-based execution.
Why Work Here
- Leading pipeline asset (eftilagimod alfa) has reached Phase 3 in NSCLC with potential Phase 2/3 data in breast cancer, offering exposure to late-stage clinical development
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 1
Clinical Trials (1)
NCT00351949IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)
Phase 1Help build intelligence for Immutep
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.